

Contents

Dedication	v
Acknowledgements	vii
Chapter 1. 50th Anniversary of Artificial Cells	1
1.1. Background	1
1.2. Starting with Artificial Red Blood Cells	2
1.3. Further Research and the First Routine Clinical Use of Artificial Cells	5
1.4. Importance of Progress in Parallel Areas of Biotechnology, Molecular Biology, and Regenerative Medicine	7
1.5. Historical Milestones	7
Chapter 2. Basic Principles	12
2.1. Basic Features of Artificial Cells	12
<i>Basic features of early artificial cells</i>	12
<i>Present status of the basic features of artificial cells of macro, micron, nano and molecular dimensions</i>	14
2.2. Nanotechnology and Nanobiotechnology	15
<i>Nanobiotechnology and artificial cells</i>	15
<i>Nanobiotechnology and the assembling of hemoglobin with enzymes that remove oxygen radicals</i>	17
<i>Nanobiotechnology for the assembling of hemoglobin with other enzymes</i>	17

	<i>Conjugation of polymer with proteins</i>	18
2.3.	Cell Homogenate, Organelle, Enzymes and Multienzyme Systems	18
	<i>Cell homogenate</i>	18
	<i>Enzymes and enzyme therapy</i>	19
	<i>Multienzyme systems with cofactor recycling</i>	20
2.4.	Artificial Cells Containing Intracellular Compartments	21
2.5.	Artificial Cells Containing Biologics and Magnetic Material	22
2.6.	Cells, Islets, Stem Cells, Genetically-engineered Cells and Microorganisms	22
	<i>Artificial cells containing cells</i>	22
	<i>Stem cells</i>	24
	<i>Genetically-engineered cells</i>	24
2.7.	Artificial Cells Containing Bioadsorbents	25
2.8.	Research on Membrane Model Systems	27
2.9.	Cell Physiology	28
2.10.	Drug Delivery	28
	<i>Polymeric semipermeable microcapsules</i>	28
	<i>Biodegradable polymeric artificial cells, nanoparticles, nanocapsules</i>	29
	<i>Liposomes — lipid membrane artificial cells</i>	29
2.11.	Other Systems	30
Chapter 3. Oxygen Carriers Based on Nanobiotechnology		31
3.1.	Introduction	31
3.2.	Hemoglobin as Oxygen Carrier	32
3.3.	Modified Hb	32
	<i>PolyHb based on nanobiotechnology (Fig. 3.1)</i>	33
	<i>Conjugated Hb (Fig. 3.1)</i>	34
	<i>Intramolecularly crosslinked single tetrameric Hb (Fig. 3.1)</i>	35
	<i>Recombinant human Hb (Fig. 3.1)</i>	35
	<i>Present status</i>	35
3.4.	PolyHb in Clinical Trials	36
3.5.	Nanobiotechnology-based PolyHb Compared with other Modified Hb	39
	<i>Vasopressor effects</i>	39

	<i>Theories why vasopressor effects are observed only in some types of modified Hb?</i>	39
	<i>Effects of tetrameric Hb on vasoactivity and ECG</i>	40
3.6.	PolyHb with <2% Tetrameric Hb	43
3.7.	Nanobiotechnology and Immunogenicity	45
	<i>Antigenicity measured as antibody titers</i>	45
	<i>Effects of infusion</i>	46
3.8.	Bridging the Gap between Safety Studies in Animal and Humans	48
	<i>In vitro screening test using human plasma before use in humans</i>	48
	<i>Basic principles of screening test</i>	49
	<i>Use in research</i>	50
	<i>Use in industrial production</i>	50
	<i>Correlation of in vitro complement activation to clinical symptoms</i>	51
	<i>Clinical trials and use in humans</i>	52
3.9.	Design of Animal Study for Hemorrhagic Shock	52
	<i>Hemorrhagic shock model</i>	52
	<i>Experimental designs</i>	53
3.10.	General Discussions	55
3.11.	Methods and Procedures	56
	<i>Special method for preparation of PolyHb containing low levels of tetrameric Hb (0.2 to 2%)</i>	56
	<i>In vitro screening test using human plasma before use in humans</i>	58
	<i>Animal study on hemorrhagic shock and exchange transfusion</i>	59
 Chapter 4. A Nanobiotechnologic Therapeutic that Transports Oxygen and Remove Oxygen Radicals: For Stroke, Hemorrhagic Shock and Related Conditions		62
4.1.	Introduction	62
4.2.	Ischemia-Reperfusion	62
4.3.	PolyHb-CAT-SOD	63
4.4.	Enzyme Activities after Intravenous Injections	64
	<i>Plasma Hb concentration</i>	64

	<i>SOD activity in plasma</i>	65
	<i>CAT activity in plasma</i>	66
	<i>Discussions</i>	66
4.5.	Tests in Animal Models for Stroke and Hemorrhagic Shock . . .	67
4.6.	Ischemia-Reperfusion of the Intestine	67
	<i>Severe hemorrhagic shock and the intestine</i>	67
	<i>Test on effects of reperfusion on ischemic intestine</i>	68
4.7.	Test in Combined Hemorrhagic Shock and Stroke Rat Model . .	69
	<i>Prolonged hemorrhagic shock and stroke model</i>	69
	<i>Rat model of combined hemorrhagic shock and stroke</i>	71
	<i>Duration of stroke and reperfusion injuries</i>	71
	<i>Effects of different solutions on reperfusion injuries</i>	72
	<i>Disruptions of blood-brain barrier</i>	72
	<i>Brain edema</i>	73
4.8.	Discussion	74
4.9.	Preparation and Characterization	75
	<i>Method of preparation</i>	75
	<i>Molecular characterization of PolyHb-CAT-SOD</i>	75
	<i>Oxygen dissociation curve</i>	77
	<i>Effects of the crosslinking procedure on metHb formation</i> . . .	77
4.10.	<i>In Vitro Studies of the Antioxidant Properties of Crosslinked HB-</i>	
	<i>SOD-CAT</i>	78
	<i>Scavenging of superoxide ($O_2^{\bullet -}$)</i>	79
	<i>Scavenging of hydrogen peroxide (H_2O_2)</i>	80
	<i>Effects of oxidative challenge on the degradation of Hb and iron</i>	
	<i>release in PolyHb and PolyHb-CAT-SOD</i>	81
	<i>Absorbance spectra and Hb degradation</i>	81
	<i>Release of iron</i>	83
	<i>Lipid peroxidation and salicylate hydroxylation</i>	84
4.11.	Methods and Procedures	85
	<i>Preparation of PolyHb-SOD-CAT</i>	85
	<i>Measurement of SOD activity</i>	86
	<i>Measurement of CAT activity</i>	87
	<i>Hydrogen peroxide scavenging</i>	87
	<i>Ratio of SOD/CAT and Hb oxidation</i>	87
	<i>Measurement of FerrylHb</i>	87

<i>Iron release study</i>	88
<i>Circulation time studies</i>	88
<i>Rat model of intestinal ischemia-reperfusion</i>	89
<i>Measurement of oxygen radical</i>	89
<i>Combined hemorrhagic shock and transient global cerebral ischemia-reperfusion</i>	90
Chapter 5. Nanotechnology-based Artificial Red Blood Cells (RBCs)	93
5.1. Introduction	93
5.2. Micron Dimension Artificial RBCs (ARBCs) with Ultrathin Polymeric Membrane	95
<i>Hemoglobin</i>	95
<i>Carbonic anhydrase</i>	95
<i>Catalase</i>	97
<i>Immunological studies</i>	97
5.3. Intravenous Injection of ARBCs	98
<i>Polymeric membrane artificial RBCs 1 micron and larger</i>	98
<i>Neuraminic acid and circulation time of red blood cells</i>	99
<i>Effects of surface charge of polymeric particles on circulation time</i>	101
<i>Artificial rbc's with sulfonated nylon membrane</i>	101
<i>Polysaccharide incorporation</i>	102
<i>Summary</i>	103
5.4. Submicron Lipid Membrane Artificial RBCs (LEH)	104
<i>Composition and preparation</i>	105
<i>Methemoglobin</i>	106
5.5. LEH in Animal Studies	107
<i>Circulation time after infusion</i>	107
<i>Safety of lipid membrane artificial rbc's</i>	108
<i>Efficacy in exchange transfusion, hemorrhagic shock and hemodilution</i>	109
<i>Summary</i>	110
5.6. Nanodimension Biodegradable Polymeric Membrane RBCs	110
<i>Introduction</i>	110
<i>Nanodimension biodegradable polymeric membrane artificial rbc's</i>	111

	<i>Safety and reasons for selection of polyesters as the biodegradable polymer membrane</i>	112
5.7.	Characterization of Nano Artificial RBCs	113
	<i>Electromicroscopic appearance</i>	113
	<i>Size distribution of polylactide membrane artificial rbc's</i>	113
	<i>Other properties</i>	114
	<i>Steady shear viscosity determination</i>	115
5.8.	Safety and Efficacy of Nano Artificial RBCs	115
	<i>Amount and fate of PLA membrane</i>	115
	<i>Efficiency in nanoencapsulating hemoglobin</i>	117
	<i>Oxygen affinity, Hill coefficient and Bohr effect</i>	117
	<i>Enzymes and multienzymes</i>	118
	<i>Nano artificial rbc's containing metHb reductase system</i>	119
	<i>Nano artificial rbc's permeable to reducing factors</i>	120
	<i>Enzymes and multienzymes in PLA nano artificial rbc's</i>	121
5.9.	Circulation Time of Nano Artificial RBCs	121
	<i>Circulation half-life of nano PLA artificial rbc's</i>	121
	<i>Different types of PEG-PLA copolymers for nano artificial rbc's</i>	121
	<i>Analysis of results</i>	126
	<i>Relevance for clinical application in humans</i>	127
5.10.	General	127
5.11.	Method of Preparation of Biodegradable Polymeric Nano Artificial RBCs	128

Chapter 6. Use of Enzyme Artificial Cells for Genetic Enzyme Defects that Increase Systemic Substrates to Toxic Levels 130

6.1.	Introduction	130
	<i>General</i>	130
	<i>Enzyme replacement therapy</i>	132
6.2.	Acatlasemia: Congenital Defect in the Enzyme Catalase	132
6.3.	Preliminary Study on the Use of Catalase Artificial Cells to Replace Defective Catalase in Acatlasemia	133
	<i>Implantation of catalase artificial cells</i>	133
	<i>Catalase artificial cells retained in a chamber for body fluid perfusion</i>	135

6.4.	<i>In Vivo Kinetics of Catalase Artificial Cells for</i>	
	Acatlasemic Mice	135
	<i>Summary</i>	135
	<i>Methods of preparation of catalase artificial cells and</i>	
	<i>experimental procedures</i>	136
	<i>Characteristics of acatalasemic mice</i>	136
	<i>Kinetics of recovery of injected perborate</i>	136
6.5.	Immunological Studies on Catalase Artificial Cells	
	in Acatlasemic Mice	137
	<i>Effects of immunizing doses of catalase solution and catalase</i>	
	<i>artificial cells on antibody production</i>	137
	<i>Permeability of membrane of collodion artificial cells</i>	
	<i>to catalase antibody</i>	138
	<i>Response of immunized acatalasemic mice to injections of</i>	
	<i>catalase artificial cells or catalase solution</i>	139
	<i>Appearance of catalase activity in the blood after</i>	
	<i>injection of catalase solution or catalase artificial cells</i>	140
6.6.	Conclusion from Results of Basic Study Using the Acatlasemic	
	Mice Model	141
6.7.	Oral Xanthine Oxidase Artificial Cells in a Patient with Lesch-	
	Nyhan Disease	142
	<i>Volume ratio of artificial cells/substrate solution</i>	143
	<i>Effects of pH on enzyme activity</i>	144
	<i>Patient with Lesch-Nyhan disease</i>	144
6.8.	Conclusion Based on Study	146
6.9.	Phenylketonuria: Genetic Defect in Enzyme Phenylalanine	
	Hydroxylase	147
	<i>Phenylketonuria</i>	147
	<i>Enzyme replacement therapy</i>	147
	<i>Oral PAL artificial cells for PKU based on novel theory</i>	
	<i>of enterorecirculation of amino acids</i>	148
6.10.	Research Leading to Proposal of Enterorecirculation of	
	Amino Acids	149
	<i>Classical theory of the main source of amino acids in</i>	
	<i>the intestinal lumen</i>	149
	<i>Research to test the classical theory</i>	149

	<i>Animals on 24 h of protein-free diet</i>	149
	<i>Results of study</i>	149
	<i>Proposed theory of extensive enterorecirculation of amino acids</i>	150
6.11.	Oral Enzyme Artificial Cells for Genetic Enzyme Defects that Result in Elevated Systemic Amino Acid Levels	152
	<i>General design for study of use of oral PAL artificial cells in PKU rats</i>	152
	<i>Methods of preparation of catalase artificial cells and experiment procedures</i>	154
	<i>Phenylketonuria rat model</i>	154
	<i>Intestinal phenylalanine</i>	154
	<i>Plasma PHE levels in PKU rats</i>	155
	<i>CSF cerebrospinal fluid in PKU rats</i>	155
	<i>Growth as shown by body weight changes</i>	155
	<i>Congenital PKU mice model</i>	157
	<i>Summary discussion</i>	158
	<i>Oral enzyme artificial cells to deplete other amino acids</i>	158
Chapter 7. Enzyme Artificial Cells in Substrate-dependent Tumors and Activation of Prodrug		160
7.1.	Introduction	160
7.2.	Asparaginase in Lymphosarcoma and Lymphoblastic Leukemia	161
7.3.	Asparaginase Artificial Cells for Lymphosarcoma	162
	<i>Asparaginase artificial cells on 6C3HED lymphosarcoma in mice (Fig. 7.2A)</i>	162
	<i>Effects on plasma asparagine level</i>	164
	<i>Asparaginase activities in the body</i>	165
	<i>Asparaginase does not leak out of artificial cells after injection</i>	166
	<i>Discussions</i>	167
7.4.	Crosslinking Asparaginase to Hemoglobin (PolyHb-Asparaginase)	168
7.5.	Crosslinking of Asparaginase to Polymer (Polyethylene Glycol — PEG)	170
7.6.	PolyHb-Tyrosinase Artificial Cells for Melanoma	172

	<i>Introduction</i>	172
	<i>Polyhemoglobin-tyrosinase for melanoma</i>	172
	<i>Studies on optimization, in vitro and in vivo</i>	
	<i>characterization</i>	176
	<i>Summary</i>	178
7.7.	Tyrosinase Artificial Cells by Oral Route	179
	<i>Introduction</i>	179
	<i>Effects of Long-term Oral Administration of Polymeric</i>	
	<i>Microcapsules Containing Tyrosinase on Maintaining</i>	
	<i>Decreased Systemic Tyrosine Levels in Rats</i>	180
	<i>Enzyme kinetics</i>	182
7.8.	Discussions on PolyHb-Tyrosinase and Tyrosinase Artificial	
	Cells	185
7.9.	Enzyme Artificial Cells for Activating Prodrugs	186
	<i>Introduction</i>	186
	<i>Clinical trial results</i>	187
7.10.	Materials and Methods	188
	<i>Asparaginase artificial cells</i>	188
	<i>PolyHb-tyrosinase in melanoma</i>	189
	<i>Preparation of PolyHb-tyrosinase</i>	189
	<i>Determination of tyrosinase activity</i>	190
	<i>Effects of intravenous injection of PolyHb-tyrosinase in rats</i>	190
	<i>B16-F10 melanoma cells and culture conditions</i>	191
	<i>Intravenous injection of PolyHb-tyrosinase in normal mice</i>	191
	<i>B16F10 melanoma bearing mice model</i>	191
	<i>Oral tyrosinase artificial cells</i>	192
	<i>Materials</i>	192
	<i>Control artificial cells</i>	192
	<i>Tyrosinase artificial cells</i>	192
	<i>In vitro studies using rat intestinal juice</i>	193
	<i>Animal studies</i>	193
	Chapter 8. Artificial Cells for Cell Encapsulation	195
8.1.	Introduction	195
8.2.	Artificial Cells Containing Islets, Liver Cells, Endocrine Cells and	
	Others	198
	<i>Artificial cells containing islets</i>	198

	<i>Artificial cells containing hepatocytes</i>	202
	<i>Other areas</i>	203
8.3.	Challenges of Artificial Cell Encapsulated Cells in Therapy . . .	203
	<i>Availability of cells</i>	203
	<i>Mass transfer, biocompatibility and stability</i>	204
	<i>Cell protrusion or entrapment in artificial cell membrane</i> . . .	205
	<i>Method to prevent cell protrusion or entrapment in artificial cell membrane</i>	207
	<i>Other improvements to microencapsulation method</i>	207
	<i>Capillary fiber cell encapsulation</i>	208
	<i>Oral administration</i>	208
8.4.	Artificial Cells Containing Genetically-engineered Cells	209
	<i>General</i>	209
	<i>Growth hormone, monoclonal antibodies, factor XI, erythropoietin</i>	210
	<i>Neurological disorders</i>	210
	<i>Tumors</i>	211
	<i>Discussions</i>	212
8.5.	Artificial Cells Containing Stem Cells	212
8.6.	Artificial Cells Containing Microorganisms	213
8.7.	Concluding Remarks	216
8.8.	Method I: Standard Alginate-Polylysine-Alginate Method	217
	<i>Materials</i>	217
	<i>Droplet generators</i>	217
8.9.	Method II: 2-Step Method	219
8.10.	Method III: Preparation of Cells for Encapsulation	221
	<i>Preparation of rat hepatocytes</i>	221
	<i>Bone marrow stem cells from rats</i>	222
	<i>Genetically-engineered E. coli DH5 cells and microorganism</i>	222
8.11.	Method IV: Artificial Cells with Macromolecular Cutoffs	223
	<i>Microorganism</i>	223
	<i>Procedure</i>	224
Chapter 9. Artificial Cells Containing Hepatocytes and/or Stem Cells in Regenerative Medicine		225
9.1.	Introduction	225

	<i>Artificial cells and regenerative medicine</i>	225
	<i>Design of study</i>	227
9.2.	Artificial Cells Containing Hepatocytes	228
	<i>Galactosamine-induced fulminant hepatic failure in rats</i>	228
	<i>Gunn rats with severe elevation of bilirubin,</i> <i>hyperbilirubinemia</i>	229
	<i>Summary</i>	231
9.3.	Immunoisolation	231
	<i>Can artificial cells protect hepatocytes from immunorejection?</i>	231
	<i>Why do rat hepatocytes inside artificial cells recover their</i> <i>viability after implantation into mice?</i>	233
	<i>Aggregation of artificial cells after implantation</i>	233
	<i>Artificial cells prepared by standard method: cell viability after</i> <i>implantation</i>	234
	<i>Artificial cells prepared by two-step method: cell viability after</i> <i>implantation</i>	236
9.4.	Artificial Cells Containing Hepatocytes or Hepatocytes Plus Stem Cells	236
	<i>Introduction</i>	236
	<i>Viability of free cells in culture</i>	237
	<i>In vitro viability of encapsulated cells</i>	237
	<i>Discussion of above results</i>	239
	<i>Study using Gunn rat model</i>	240
9.5.	Artificial Cells Containing Hepatocytes in Rats with 90% of Liver Surgically Removed	241
	<i>Introduction</i>	241
	<i>Artificial cells prepared using 2-step method on survival of rats</i> <i>with 90% of liver surgically removed</i>	241
	<i>Factors to be considered</i>	242
9.6.	Artificial Cells Containing Bone Marrow Stem Cells	243
	<i>Viability of isolated cells</i>	244
	<i>Survival rates of rats with 90% of liver surgically removed</i> . . .	244
	<i>Remnant liver weight</i>	246
	<i>Blood chemistry</i>	246
	<i>Plasma hepatic growth factor (HGF) levels</i>	246
	<i>Laparotomy and histology</i>	247

	<i>Immunocytochemistry</i>	249
	<i>PAS glycogen stain</i>	249
	<i>Possible mechanisms responsible for recovery of 90% hepatectomized rat model</i>	249
9.7.	Artificial Cells Containing Stem Cells in Regeneration Medicine	251
Chapter 10. Hemoperfusion in Poisoning, Kidney Failure, Liver Failure, and Immunology		252
10.1.	Introduction	252
	<i>Artificial kidney machine</i>	252
	<i>Hemoperfusion based on artificial cells</i>	252
10.2.	Development and Clinical Trials	253
	<i>Treatment of patients with severe accidental or suicidal poisoning</i>	255
	<i>Hemoperfusion for removal of unwanted or toxic substances from blood under other conditions</i>	256
	<i>Treatment of patients with terminal kidney failure</i>	256
	<i>Treatment of patients with hepatic coma</i>	257
	<i>Protein-coated artificial cells in immunoabsorption</i>	258
10.3.	Basic Principle of Artificial Cell in Hemoperfusion	258
	<i>Permeability and transport characteristics</i>	258
	<i>Experimental analysis</i>	260
10.4.	Artificial Cells Containing Activated Charcoal in Hemoperfusion	261
	<i>Why use activated charcoal for artificial cell hemoperfusion?</i>	261
	<i>Effects on embolism</i>	262
	<i>Effects of hemoperfusion on platelets</i>	262
	<i>Clearance of the ACAC artificial cell artificial kidney</i>	263
	<i>Improvements in hydrodynamics</i>	265
10.5.	Hemoperfusion in Acute Suicidal or Accidental Poisoning	266
	<i>Preclinical studies</i>	266
	<i>First clinical trials in acute poisoning</i>	266
	<i>Result of clinical trials on 11 adult patients with suicidal or accidental drug poisoning</i>	267
	<i>Pediatric patient with accidental theophylline overdose</i>	273
	<i>Routine clinical uses in patients around the world</i>	275

10.6. Hemoperfusion in Terminal Renal Failure Patients 276

10.7. Hemoperfusion Alone Supplemented by Hemodialysis 279

General clinical results 279

First patient on long-term hemoperfusion 279

Hemoperfusion and removal of uremic metabolites 283

10.8. Conjoint Hemoperfusion-Hemodialysis 283

10.9. Miniaturized Artificial Kidney Based on Hemoperfusion-Ultrafiltration 286

10.10. Hemoperfusion in Liver Failure 288

First observation of recovery of consciousness in hepatic coma 288

Results around the world on effect of hemoperfusion on hepatic coma 290

Control studies in galactosamine-induced hepatic failure rats . 291

10.11. Immunoabsorption 294

Protein coated artificial cells in immunoabsorption 294

10.12. Detailed Procedures for the Laboratory Preparation of ACAC Hemoperfusion Device 295

The extracorporeal shunt chamber 295

Preparation of activated charcoal 295

Preparation of artificial cells containing activated charcoal . . . 296

Procedure for hemoperfusion 297

Chapter 11. Perspectives on the Future of Artificial Cells as Suggested by Past Research 299

11.1. Introduction 299

11.2. Membrane Material 300

11.3. Polymeric Membrane 300

Porosity of polymeric membrane of artificial cells 300

11.4. Lipid Membrane Artificial Cells 304

11.5. Artificial Cells with Lipid-Polymer Membrane and Incorporation of Macrocyclic Carrier, NA-K-ATPase and Other Carriers . . . 305

Artificial cells with lipid-polymer membrane 305

Incorporation of channels into lipid-polymer membrane of artificial cells 307

Incorporation of Na-K-ATPase in the membrane of artificial cells 310

Nanobiosensors 312

11.6.	Surface Properties of Artificial Cell Membranes	312
11.7.	Drug Delivery	314
	<i>General</i>	314
	<i>Polymeric semipermeable microcapsules</i>	316
	<i>Biodegradable polymeric artificial cells, nanoparticles,</i> <i>nanocapsules</i>	316
	<i>Liposomes evolved into lipid vesicles that are lipid membrane</i> <i>artificial cells</i>	316
	<i>Polymer(PEG)-lipid membrane artificial cells or PEG-lipid</i> <i>vesicles</i>	318
	<i>Polymersomes: polymeric membrane artificial cells</i>	319
11.8.	Artificial Cells Containing Multienzyme Systems with Recycling of ATP and NADH	320
	<i>Artificial cells containing multienzyme system for recycling of</i> <i>ATP</i>	320
	<i>Artificial cells containing multienzyme system for recycling of</i> <i>NAD(P)H</i>	320
	<i>Artificial cells containing urease, glutamate dehydrogenase and</i> <i>glucose-6-phosphate dehydrogenase</i>	321
	<i>Dextran-NADH retained and recycled inside artificial cells</i> <i>(Fig. 11.4)</i>	322
	<i>Multienzyme with NAD-dextran for conversion of waste, urea,</i> <i>into useful essential amino acids</i>	324
	<i>Recycling of free NADH retained within the lipid-polymer</i> <i>membrane artificial cells for conversion of urea into amino</i> <i>acid</i>	324
	<i>Summary</i>	327
11.9.	Artificial Cells Containing Microsomes, Cytosol Ribosomes and Polymerases	327
	<i>Introduction</i>	327
	<i>Artificial cells containing liver microsomes and cytosol</i>	328
	<i>Towards a “living” artificial cell containing polymerases,</i> <i>ribosomes and transcription/translation system</i>	328
11.10.	New Generations of Computer System and Nanoscale Robotics Based on Artificial Cells	331
11.11.	The Future of Artificial Cells	332

Appendix I. 1957 Report on "Method for Preparing Artificial Hemoglobin Corpuscles"	335
ERYTHROCYTES	335
1. <i>Structure</i>	335
2. <i>Function</i>	336
3. <i>Enzymes and inclusion bodies</i>	336
HEMOGLOBIN	337
1. <i>Molecular structure</i>	337
2. <i>Hemoglobin content of the blood</i>	337
3. <i>Methemoglobin</i>	337
4. <i>Derivatives of hemoglobin</i>	338
MEMBRANE	338
1. <i>Reason for using collodion membrane</i>	338
2. <i>Studies made on collodion membrane</i>	339
3. <i>Final constituents of collodion solution used in this experiment</i>	339
METHOD	340
<i>Method I</i>	340
<i>Method II</i>	343
<i>Experimentation with collodion</i>	343
<i>Method III</i>	343
<i>Method IV — successful method</i>	344
<i>Procedure</i>	345
<i>Proof that collodion membrane is formed</i>	347
RESULTS	348
<i>i. Size of corpuscles</i>	348
<i>ii. Content of corpuscles</i>	348
<i>iii. Oxygen content</i>	348
DISCUSSIONS	350
<i>Transportation of O₂ and CO₂</i>	351
<i>Enzyme systems in the erythrocyte</i>	353
<i>Buffering action of erythrocyte</i>	353
SUMMARY	354
BIBLIOGRAPHY	354

Appendix II. Methods not Described in Detail in the 11 Chapters	355
A. EMULSION METHODS FOR ARTIFICIAL CELLS	355
A.1. Cellulose nitrate membrane artificial cells of micro dimensions	355
A.2. Polyamide membrane artificial cells of micro dimensions .	357
A.3. Lipid-polymer membrane artificial cells of micro dimensions that retain ATP and NAD(P)H	360
A.4. Double emulsion methods	361
B. DROP METHODS FOR LARGER ARTIFICIAL CELLS	362
B.1. Polymer membrane artificial cells	362
B.2. Lipid-polymer membrane artificial cells	364
B.3. Lipid-polymer membrane artificial cells with macrocyclic carrier	365
B.4. Incorporation of Na-K-ATPase to membrane of artificial cells	365
B.5. Standard alginate-polylysine-alginate artificial cells (tissues, cells, microorganisms)	366
B.6. Two-step method for alginate-polylysine-alginate artificial cells (tissues, cells, microorganisms)	372
B.7. Macroporous agar membrane artificial cells	374
References	377
Index	441